In a significant development for the computational biology industry, Velsera, a front-runner in the advancement of precision medicine, has officially announced Jamie Littlejohns as its new Chief Executive Officer, effective from March 1, 2024.
Jamie Littlejohns steps into the CEO role at Velsera, bringing a rich background from his tenure at McKinsey, where he served as a Partner and spearheaded the firm’s European Healthcare & Life Sciences Private Equity Practice. Since 2010, Littlejohns has been instrumental in guiding health and life science tech companies through significant scale-up phases across Europe, the US, and Australia. His involvement with Velsera dates back to early 2022, where he contributed in an advisory capacity, marking the beginning of his journey with the company.
Reflecting on his appointment, Littlejohns expressed his enthusiasm, emphasizing Velsera’s potential to revolutionize precision medicine. He highlighted the company’s capabilities in speeding up drug discovery, enhancing the accessibility of innovative diagnostics and treatments, and refining patient care decisions. Littlejohns is committed to driving Velsera’s growth and collaborating closely with customers to foster advancements in precision medicine.
Hans Cobben, transitioning back to his role as Chairman of the Board, voiced the board’s unanimous support for Littlejohns. Cobben praised Jamie’s proven track record in accelerating the growth of similar enterprises and his ability to seamlessly integrate into Velsera, thanks to his prior engagements with the company and its predecessors. Cobben eagerly looks forward to Velsera’s continued expansion and success under Littlejohns’s leadership.
For more insights into Velsera’s mission and leadership, interested parties are encouraged to visit www.velsera.com.
